Last reviewed · How we verify
NCT06909266: IVANS
Impact of Vestibular Function on Deaf Infants' Activities of Daily Living
trial testing OT Hope 0 - 5 ans Therapeutic tool in Vestibular Dysfunction in 105 participants. Not yet recruiting.
1 April 2028
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 105 |
| Start date | 27 March 2025 |
| Primary completion | 1 April 2028 |
| Estimated completion | 1 April 2028 |
| Sites | 1 location across France |
Drugs / interventions tested
- OT Hope 0 - 5 ans Therapeutic tool
- Qualitative interviews with parents
Conditions studied
- Vestibular Dysfunction — all drugs for Vestibular Dysfunction →
- Hearing Loss — all drugs for Hearing Loss →
- Motor Development — all drugs for Motor Development →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
Adults 1 Day to 2, any sex, with Vestibular Dysfunction or Hearing Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This non-interventional study aims to assess the impact of vestibular impairments on the daily life activities of deaf children aged 0 to 2 years old. Three groups of participants will be included: deaf children with vestibular impairment, deaf children without vestibular impairment, and hearing children without vestibular dysfunction (control group). Children's daily activities will be evaluated through the OT Hope 0-5 years tool, a parent-administered questionnaire designed to measure competencies in different areas: personal care, play, and social interactions. This study also includes qualitative interviews with parents to further explore how vestibular impairments affect children's daily routines. It is hypothesized that: * Deaf children with vestibular impairments will show lower scores in daily life activities compared to the other two groups. * Deaf children without vestibular impairments will demonstrate scores closer to those of hearing children but may show some differences due to their hearing status. The research is conducted at the Robert Debré Hospital, in Paris, and aims to enroll 105 children over a three-year period. The data collected will provide insights into the specific needs of children with vestibular impairments and lay the groundwork for targeted early interventions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06909266
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06909266 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06909266.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing